Rituximab instead of splenectomy in 4 children with chronic or refractory autoimmune haemolytic anaemia;Rituximab in plaats van splenectomie bij 4 kinderen met chronische of refractaire auto-immune hemolytische anemie

Nederlands Tijdschrift voor Geneeskunde

Volumn 149, Issue 42, 2005, Pages 2350-2354

  Van Daalen, S T H ^a,b   Van Dijken, P J ^c   Tamminga, R Y J ^d   Brons, P P T ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Afd Kindergeneeskunde ^*  (Netherlands)

^c Microvida Laboratory for Medical Microbiology and Immunology   (Netherlands)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; BILIRUBIN; CORTICOSTEROID; HEMOGLOBIN; IMMUNOGLOBULIN; LACTATE DEHYDROGENASE; RITUXIMAB; STEROID;

ADOLESCENT; ANTIBODY PRODUCTION; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; B LYMPHOCYTE; BLOOD TRANSFUSION; CELL DESTRUCTION; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MEGADOSE; DRUG TOLERABILITY; ENZYME ACTIVITY; FEMALE; HEMOLYSIS; HUMAN; INFECTION; MALE; REFRACTORY ANEMIA; RETICULOCYTE COUNT; SCHOOL CHILD; SPLENECTOMY;

ADOLESCENT; ANEMIA, HEMOLYTIC, AUTOIMMUNE; ANTIBODIES, MONOCLONAL; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MALE; SPLENECTOMY; TREATMENT OUTCOME;

EID: 27144455820     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Ware RE, Rosse WF. Autoimmune hemolytic anemia. In: Nathan DG, Orkin SH, editors. Nathan and Oski's hematology of infancy and childhood. Philadelphia: Saunders; 1998. p. 499-522.
2. Izui S. Autoimmune hemolytic anemia. Curr Opin Immunol. 1994;6:926-30.
3. Jansen MJCE, Bax NMA, Révész T, Sanders EAM. Splenectomie bij kinderen; indicaties en chirurgische aspecten. Ned Tijdschr Geneeskd. 2003;147:433-6.
4. Coiffier B, Haioun C, Ketterer N, Engert A, Tilly H, Ma D, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood. 1998;92:1927-32.
5. Ahrens N, Kingreen D, Seltsam A, Salama A. Treatment of refractory autoimmune haemolytic anaemia with anti-CD20 (rituximab). Br J Haematol. 2001;114:244-5.
6. Zecca M, de Stefano P, Nobili B, Locatelli F. Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia. Blood. 2001;97:3995-7.
7. Quartier P, Brethon B, Philippet P, Landman-Parker J, le Deist F, Fischer A. Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet. 2001;358:1511-3.
8. Zecca M, Nobili B, Ramenghi U, Perrotta S, Amendola G, Rosito P, et al. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood. 2003;101:3857-61.
9. Shanafelt TD, Madueme HL, Wolf RC, Tefferi A. Rituximab for immune cytopenia in adults: idiopathic trombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome. Mayo Clin Proc. 2003;78:1340-6.
10. Sharma VR, Fleming DR, Slone SP. Pure red cell aplasia due to parvovirus B 19 in a patient treated with rituximab. Blood. 2000;96:1184-6.
11. Song KW, Mollee P, Patterson B, Brien W, Crump M. Pure red cell aplasia due to parvovirus following treatment with CHOP and rituximab for B-cell lymphoma. Br J Haematol. 2002;119:125-7.
12. Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med. 2001;344:68-9.
13. Roosnek E, Lanzavecchia A. Efficient and selective presentation of antigen-antibody complexes by rheumatoid factor B cells. J Exp Med. 1991;173:487-9.
14. Edwards JCW, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford). 2001;40:205-11.
15. Stasi R, Pagano A, Stipa E, Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood. 2001;98:952-7.